KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Non-Current Debt (2018 - 2025)

Takeda Pharmaceutical (TAK) has 8 years of Non-Current Debt data on record, last reported at $3.6 billion in Q1 2025.

  • For Q1 2025, Non-Current Debt fell 22.2% year-over-year to $3.6 billion; the TTM value through Mar 2025 reached $3.6 billion, down 22.2%, while the annual FY2025 figure was $3.6 billion, 24.17% down from the prior year.
  • Non-Current Debt reached $3.6 billion in Q1 2025 per TAK's latest filing, down from $4.6 billion in the prior quarter.
  • Across five years, Non-Current Debt topped out at $35.6 billion in Q1 2022 and bottomed at $3.6 billion in Q1 2025.
  • Average Non-Current Debt over 5 years is $10.6 billion, with a median of $4.6 billion recorded in 2024.
  • Peak YoY movement for Non-Current Debt: skyrocketed 628.65% in 2022, then crashed 88.67% in 2023.
  • A 5-year view of Non-Current Debt shows it stood at $4.9 billion in 2021, then surged by 628.65% to $35.6 billion in 2022, then plummeted by 88.67% to $4.0 billion in 2023, then rose by 14.91% to $4.6 billion in 2024, then dropped by 22.2% to $3.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $3.6 billion in Q1 2025, $4.6 billion in Q1 2024, and $4.0 billion in Q1 2023.